Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
1998 2
1999 6
2000 11
2001 9
2002 19
2003 40
2004 49
2005 82
2006 46
2007 69
2008 79
2009 72
2010 65
2011 63
2012 51
2013 70
2014 78
2015 50
2016 57
2017 47
2018 46
2019 31
2020 34
2021 45
2022 43
2023 32
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

1,084 results

Results by year

Filters applied: . Clear all
Page 1
Sevelamer carbonate.
Barna MM, Kapoian T, O'Mara NB. Barna MM, et al. Ann Pharmacother. 2010 Jan;44(1):127-34. doi: 10.1345/aph.1M291. Epub 2009 Dec 2. Ann Pharmacother. 2010. PMID: 19955298 Review.
Additionally, sevelamer hydrochloride was removed from the market in October 2009; sevelamer carbonate is now the only available formulation. CONCLUSIONS: Sevelamer carbonate is a treatment option for hyperphosphatemia in patients with CKD who a …
Additionally, sevelamer hydrochloride was removed from the market in October 2009; sevelamer carbonate is now the only …
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, den Adel M, van Dijk J, Golor G, Schaddelee M. Groenendaal-van de Meent D, et al. Clin Ther. 2021 Jun;43(6):1079-1091. doi: 10.1016/j.clinthera.2021.03.025. Epub 2021 May 5. Clin Ther. 2021. PMID: 33962762 Free article. Clinical Trial.
On day 1 of each period, participants received 200 mg roxadustat administered alone or (1) concomitantly with sevelamer carbonate (2400 mg) or calcium acetate (1900 mg) (part 1) or (2) 1 hour before or 1, 2, or 3 hours after sevelamer carbonate (part 2 …
On day 1 of each period, participants received 200 mg roxadustat administered alone or (1) concomitantly with sevelamer carbonate …
Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.
Vlassara H, Cai W, Chen X, Serrano EJ, Shobha MS, Uribarri J, Woodward M, Striker GE. Vlassara H, et al. J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1410-6. doi: 10.1093/gerona/gls195. Epub 2012 Oct 29. J Gerontol A Biol Sci Med Sci. 2012. PMID: 23109677 Free PMC article. Review.
This communication reviews these data and adds new information on the efficacy of a drug, sevelamer carbonate, required to reduce ROS and/or inflammation in the aging type 2 diabetes patient complicated by CKD. ...
This communication reviews these data and adds new information on the efficacy of a drug, sevelamer carbonate, required to red …
Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.
Perry CM, Plosker GL. Perry CM, et al. Drugs. 2014 May;74(7):771-92. doi: 10.1007/s40265-014-0215-7. Drugs. 2014. PMID: 24811546 Review.
In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels 1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require …
In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis …
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30132304 Free PMC article.
Thirty studies compared sevelamer to calcium (5424 participants), and fourteen studies compared lanthanum to calcium (1690 participants). No study compared iron-based binders to calcium. The remaining studies evaluated comparisons between sevelamer (hydrochloride or …
Thirty studies compared sevelamer to calcium (5424 participants), and fourteen studies compared lanthanum to calcium (1690 participan …
Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.
Padhi D, Harris R, Sullivan JT. Padhi D, et al. Clin Drug Investig. 2014 Aug;34(8):537-44. doi: 10.1007/s40261-014-0206-1. Clin Drug Investig. 2014. PMID: 24935051 Clinical Trial.
The objective of this study was to assess the effects of concomitantly administered therapies of calcium carbonate (CaCO(3); TUMS()), sevelamer hydrochloride (HCl; Renagel()) and pantoprazole sodium (Protonix()) on the pharmacokinetics and safety of cinacalcet in he …
The objective of this study was to assess the effects of concomitantly administered therapies of calcium carbonate (CaCO(3); TUMS()), …
Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB, Shepler BM. Pai AB, et al. Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Pharmacotherapy. 2009. PMID: 19397463 Review.
However, reported drawbacks of this agent are metabolic acidosis, high pill burden, and a relatively low affinity and selectivity for phosphate anions. Sevelamer carbonate is a new buffered formulation that does not increase the risk of metabolic acidosis. ...Severa …
However, reported drawbacks of this agent are metabolic acidosis, high pill burden, and a relatively low affinity and selectivity for phosph …
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. Pergola PE, et al. J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. doi: 10.1681/ASN.2020101398. Epub 2021 Mar 25. J Am Soc Nephrol. 2021. PMID: 33766811 Free PMC article. Clinical Trial.
METHODS: This double-blind phase 3 trial enrolled 236 patients undergoing maintenance dialysis with hyperphosphatemia (defined in this trial as serum phosphorus 5.5-10 mg/dl inclusive) despite receiving phosphate binder therapy (sevelamer, nonsevelamer, sevelamer pl …
METHODS: This double-blind phase 3 trial enrolled 236 patients undergoing maintenance dialysis with hyperphosphatemia (defined in this trial …
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J. Covic AC, et al. Nephron. 2020;144(9):428-439. doi: 10.1159/000507258. Epub 2020 Jun 25. Nephron. 2020. PMID: 32585670 Free PMC article. Clinical Trial.
METHODS: Post hoc analyses were performed using data for patients with hyperphosphatemia who received 52 weeks of treatment with sucroferric oxyhydroxide (SFOH) or sevelamer carbonate (sevelamer). Patients were categorized into those who achieved sP control ( …
METHODS: Post hoc analyses were performed using data for patients with hyperphosphatemia who received 52 weeks of treatment with sucroferric …
1,084 results